Cardiac events in adults with aggressive B-cell lymphoma treated with CAR-T therapy
Cardiovascular Events Among Adults Patients With Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy: A Single-Institution Experience
This study looks at heart problems that adults with aggressive B-cell lymphoma might have after receiving CAR-T therapy to better understand the safety of this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | CAR-T, chimeric antigen receptor |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04870853 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize cardiac events that occur following standard of care chimeric antigen receptor T (CAR-T) cell therapy in adult patients with relapsed or refractory aggressive B-cell lymphoma. The study involves a retrospective review of patients' medical records to gather data on the incidence, management, and outcomes of these cardiac events. By analyzing this information, the study seeks to provide insights into the safety profile of CAR-T therapy in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with aggressive B-cell lymphoma who have received CAR-T therapy.
Not a fit: Patients who have not undergone CAR-T therapy or those with other types of lymphoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding of cardiac risks associated with CAR-T therapy, leading to better management strategies for patients.
How similar studies have performed: While there have been studies on CAR-T therapy, this specific focus on cardiac events is novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (\>= 18 years) with a diagnosis of aggressive B-cell lymphoma (such as transformed follicular lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and high-grade B-cell lymphoma), who received standard of care (SOC) chimeric antigen receptor T (CAR-T) cell therapy at MD Anderson Cancer Center Exclusion Criteria: * None
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Raphael E Steiner — M.D. Anderson Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.